CRISPR Therapeutics (CRSP) Competitors

$54.01 -0.82 (-1.50%)

Closing price 04:00 PM Eastern

Extended Trading

$54.75 +0.74 (+1.37%)

As of 06:05 PM Eastern

CRSP vs. ALLO, AXSM, BEAM, EDIT, and KALA

Should you be buying CRISPR Therapeutics stock or one of its competitors? The main competitors of CRISPR Therapeutics include Allogene Therapeutics (ALLO), Axsome Therapeutics (AXSM), Beam Therapeutics (BEAM), Editas Medicine (EDIT), and KALA BIO (KALA). These companies are all part of the "pharmaceutical products" industry.

How does CRISPR Therapeutics compare to Allogene Therapeutics?

Allogene Therapeutics (NASDAQ:ALLO) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

Allogene Therapeutics has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.74, indicating that its stock price is 74% more volatile than the S&P 500.

Allogene Therapeutics currently has a consensus target price of $8.44, suggesting a potential upside of 270.11%. CRISPR Therapeutics has a consensus target price of $66.06, suggesting a potential upside of 22.32%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Allogene Therapeutics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73
CRISPR Therapeutics	2 Sell rating(s)	5 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.56

In the previous week, CRISPR Therapeutics had 36 more articles in the media than Allogene Therapeutics. MarketBeat recorded 39 mentions for CRISPR Therapeutics and 3 mentions for Allogene Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.38 beat Allogene Therapeutics' score of 0.00 indicating that CRISPR Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allogene Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CRISPR Therapeutics	9 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	3 Very Negative mention(s)	Neutral

Allogene Therapeutics has higher earnings, but lower revenue than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	N/A	N/A	-$190.89M	-$0.87	N/A
CRISPR Therapeutics	$1M	5,209.21	-$581.60M	-$6.22	N/A

83.6% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are held by institutional investors. 13.2% of Allogene Therapeutics shares are held by company insiders. Comparatively, 4.3% of CRISPR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Allogene Therapeutics has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-57.07%	-41.63%
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%

Summary

Allogene Therapeutics beats CRISPR Therapeutics on 8 of the 14 factors compared between the two stocks.

How does CRISPR Therapeutics compare to Axsome Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership.

Axsome Therapeutics has higher revenue and earnings than CRISPR Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$1M	5,209.21	-$581.60M	-$6.22	N/A
Axsome Therapeutics	$708.24M	15.73	-$183.17M	-$3.73	N/A

CRISPR Therapeutics presently has a consensus target price of $66.06, suggesting a potential upside of 22.32%. Axsome Therapeutics has a consensus target price of $251.26, suggesting a potential upside of 16.07%. Given CRISPR Therapeutics' higher possible upside, equities analysts clearly believe CRISPR Therapeutics is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	2 Sell rating(s)	5 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.56
Axsome Therapeutics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90

Axsome Therapeutics has a net margin of -26.59% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 4.3% of CRISPR Therapeutics shares are owned by company insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Axsome Therapeutics had 1 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 40 mentions for Axsome Therapeutics and 39 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.38 beat Axsome Therapeutics' score of 0.23 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	9 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	3 Very Negative mention(s)	Neutral
Axsome Therapeutics	13 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

CRISPR Therapeutics has a beta of 1.74, meaning that its share price is 74% more volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500.

Summary

Axsome Therapeutics beats CRISPR Therapeutics on 9 of the 16 factors compared between the two stocks.

How does CRISPR Therapeutics compare to Beam Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Beam Therapeutics (NASDAQ:BEAM) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

Beam Therapeutics has higher revenue and earnings than CRISPR Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$1M	5,209.21	-$581.60M	-$6.22	N/A
Beam Therapeutics	$164.01M	19.89	-$79.99M	-$0.68	N/A

CRISPR Therapeutics currently has a consensus target price of $66.06, suggesting a potential upside of 22.32%. Beam Therapeutics has a consensus target price of $47.17, suggesting a potential upside of 48.56%. Given Beam Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Beam Therapeutics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	2 Sell rating(s)	5 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.56
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71

Beam Therapeutics has a net margin of -39.66% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%
Beam Therapeutics	-39.66%	-29.00%	-22.61%

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 4.3% of CRISPR Therapeutics shares are owned by insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, CRISPR Therapeutics had 28 more articles in the media than Beam Therapeutics. MarketBeat recorded 39 mentions for CRISPR Therapeutics and 11 mentions for Beam Therapeutics. Beam Therapeutics' average media sentiment score of 0.57 beat CRISPR Therapeutics' score of 0.38 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	9 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	3 Very Negative mention(s)	Neutral
Beam Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

CRISPR Therapeutics has a beta of 1.74, meaning that its share price is 74% more volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 2.26, meaning that its share price is 126% more volatile than the S&P 500.

Summary

Beam Therapeutics beats CRISPR Therapeutics on 9 of the 16 factors compared between the two stocks.

How does CRISPR Therapeutics compare to Editas Medicine?

CRISPR Therapeutics (NASDAQ:CRSP) and Editas Medicine (NASDAQ:EDIT) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, media sentiment, dividends, valuation, analyst recommendations and profitability.

Editas Medicine has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$1M	5,209.21	-$581.60M	-$6.22	N/A
Editas Medicine	$38.69M	7.74	-$160.06M	-$1.23	N/A

Editas Medicine has a net margin of -281.59% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%
Editas Medicine	-281.59%	-677.39%	-58.25%

In the previous week, CRISPR Therapeutics had 23 more articles in the media than Editas Medicine. MarketBeat recorded 39 mentions for CRISPR Therapeutics and 16 mentions for Editas Medicine. CRISPR Therapeutics' average media sentiment score of 0.38 beat Editas Medicine's score of 0.12 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	9 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	3 Very Negative mention(s)	Neutral
Editas Medicine	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	4 Negative mention(s)	2 Very Negative mention(s)	Neutral

CRISPR Therapeutics presently has a consensus target price of $66.06, suggesting a potential upside of 22.32%. Editas Medicine has a consensus target price of $5.40, suggesting a potential upside of 76.47%. Given Editas Medicine's stronger consensus rating and higher probable upside, analysts clearly believe Editas Medicine is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	2 Sell rating(s)	5 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.56
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

CRISPR Therapeutics has a beta of 1.74, indicating that its share price is 74% more volatile than the S&P 500. Comparatively, Editas Medicine has a beta of 2.14, indicating that its share price is 114% more volatile than the S&P 500.

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 71.9% of Editas Medicine shares are held by institutional investors. 4.3% of CRISPR Therapeutics shares are held by insiders. Comparatively, 2.1% of Editas Medicine shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Editas Medicine beats CRISPR Therapeutics on 9 of the 17 factors compared between the two stocks.

How does CRISPR Therapeutics compare to KALA BIO?

CRISPR Therapeutics (NASDAQ:CRSP) and KALA BIO (NASDAQ:KALA) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability.

KALA BIO has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%
KALA BIO	N/A	-12,971.16%	-90.83%

In the previous week, CRISPR Therapeutics had 33 more articles in the media than KALA BIO. MarketBeat recorded 39 mentions for CRISPR Therapeutics and 6 mentions for KALA BIO. CRISPR Therapeutics' average media sentiment score of 0.38 beat KALA BIO's score of -0.37 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	9 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	3 Very Negative mention(s)	Neutral
KALA BIO	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

CRISPR Therapeutics currently has a consensus target price of $66.06, suggesting a potential upside of 22.32%. KALA BIO has a consensus target price of $1,018.75, suggesting a potential upside of 25,954.99%. Given KALA BIO's higher probable upside, analysts plainly believe KALA BIO is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	2 Sell rating(s)	5 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.56
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

CRISPR Therapeutics has a beta of 1.74, indicating that its stock price is 74% more volatile than the S&P 500. Comparatively, KALA BIO has a beta of -2.23, indicating that its stock price is 323% less volatile than the S&P 500.

KALA BIO has lower revenue, but higher earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$1M	5,209.21	-$581.60M	-$6.22	N/A
KALA BIO	N/A	N/A	-$26.98M	-$3.33	N/A

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 24.6% of KALA BIO shares are owned by institutional investors. 4.3% of CRISPR Therapeutics shares are owned by insiders. Comparatively, 2.2% of KALA BIO shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

CRISPR Therapeutics beats KALA BIO on 11 of the 16 factors compared between the two stocks.

Get CRISPR Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRSP vs. The Competition

Export

Metric	CRISPR Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.21B	$3.37B	$6.18B	$12.27B
Dividend Yield	N/A	2.24%	2.78%	5.22%
P/E Ratio	-8.68	15.19	20.66	25.70
Price / Sales	5,209.21	189.41	528.16	64.14
Price / Cash	N/A	56.93	27.81	36.27
Price / Book	2.68	6.94	9.77	6.74
Net Income	-$581.60M	$24.11M	$3.54B	$333.09M
7 Day Performance	N/A	N/A	N/A	0.52%
1 Month Performance	5.45%	4.62%	6.25%	8.97%
1 Year Performance	51.63%	78.20%	41.74%	42.42%

CRISPR Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRSP CRISPR Therapeutics	2.614 of 5 stars	$54.01 -1.5%	$66.06 +22.3%	+53.9%	$5.21B	$1M	N/A	460	Earnings Report Analyst Upgrade
ALLO Allogene Therapeutics	2.9691 of 5 stars	$2.26 +5.1%	$8.44 +273.4%	+96.6%	$553.29M	$20K	N/A	310	Upcoming Earnings
AXSM Axsome Therapeutics	3.3974 of 5 stars	$224.03 +8.5%	$234.21 +4.5%	+101.7%	$11.52B	$638.50M	N/A	380	Earnings Report High Trading Volume
BEAM Beam Therapeutics	3.3874 of 5 stars	$30.08 -2.0%	$49.36 +64.1%	+85.5%	$3.09B	$139.74M	N/A	510	Earnings Report
EDIT Editas Medicine	3.4624 of 5 stars	$3.00 +3.4%	$5.30 +76.7%	+114.5%	$293.73M	$40.52M	N/A	230	Earnings Report Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRSP) was last updated on 5/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CRISPR Therapeutics (CRSP) Competitors

CRSP vs. ALLO, AXSM, BEAM, EDIT, and KALA

How does CRISPR Therapeutics compare to Allogene Therapeutics?

Summary

How does CRISPR Therapeutics compare to Axsome Therapeutics?

Summary

How does CRISPR Therapeutics compare to Beam Therapeutics?

Summary

How does CRISPR Therapeutics compare to Editas Medicine?

Summary

How does CRISPR Therapeutics compare to KALA BIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRSP vs. The Competition

CRISPR Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CRISPR Therapeutics (CRSP) Competitors

CRSP vs. ALLO, AXSM, BEAM, EDIT, and KALA

How does CRISPR Therapeutics compare to Allogene Therapeutics?

Which has more risk & volatility, ALLO or CRSP?

Do analysts rate ALLO or CRSP?

Does the media favor ALLO or CRSP?

Which has better valuation and earnings, ALLO or CRSP?

Do institutionals & insiders hold more shares of ALLO or CRSP?

Is ALLO or CRSP more profitable?

Summary

How does CRISPR Therapeutics compare to Axsome Therapeutics?

Which has stronger valuation and earnings, CRSP or AXSM?

Do analysts recommend CRSP or AXSM?

Is CRSP or AXSM more profitable?

Do insiders and institutionals hold more shares of CRSP or AXSM?

Does the media prefer CRSP or AXSM?

Which has more risk and volatility, CRSP or AXSM?

Summary

How does CRISPR Therapeutics compare to Beam Therapeutics?

Which has better valuation & earnings, CRSP or BEAM?

Do analysts rate CRSP or BEAM?

Is CRSP or BEAM more profitable?

Do institutionals & insiders hold more shares of CRSP or BEAM?

Does the media refer more to CRSP or BEAM?

Which has more risk & volatility, CRSP or BEAM?

Summary

How does CRISPR Therapeutics compare to Editas Medicine?

Which has higher valuation & earnings, CRSP or EDIT?

Is CRSP or EDIT more profitable?

Does the media favor CRSP or EDIT?

Do analysts prefer CRSP or EDIT?

Which has more volatility & risk, CRSP or EDIT?

Do insiders and institutionals have more ownership in CRSP or EDIT?

Summary

How does CRISPR Therapeutics compare to KALA BIO?

Is CRSP or KALA more profitable?

Does the media refer more to CRSP or KALA?

Do analysts prefer CRSP or KALA?

Which has more risk & volatility, CRSP or KALA?

Which has stronger earnings & valuation, CRSP or KALA?

Do institutionals and insiders have more ownership in CRSP or KALA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRSP vs. The Competition

CRISPR Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools